Psychologists in Nutley, NJ Accepting Medicare
6 Psychologists found. Showing 1 - 6
 Dr. Marissa Koziar, PH.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 138 Beech St, Nutley, NJ 07110 Phone: 862-208-9418 |
Dr. Grace Ann Furnari, PSY.D., BCBA-D Psychologist Medicare: Not Enrolled in Medicare Practice Location: 596 Franklin Ave, Nutley, NJ 07110 Phone: 973-420-6644 |
Dr. Daria Luongo, PSY.D., LPC, NCC Psychologist - Counseling Medicare: Medicare Enrolled Practice Location: 10 Freeman Pl, Nutley, NJ 07110 Phone: 201-396-8932 |
 Dr. Mark Lyall, PSY.D Psychologist Medicare: Not Enrolled in Medicare Practice Location: 610 Franklin Ave, Nutley, NJ 07110 Phone: 973-798-2536 |
Ms. Sonja Maria Ramirez, PH.D. CLINICAL PSYCH Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: Ramirez Behavioral Healthcare, Llc, Sonja M. Ramirez Phd - 25 River Rd Apt 2a, Nutley, NJ 07110 Phone: 973-930-2915 |
David L Berkovitz, PHD Psychologist - Clinical Medicare: Accepting Medicare Assignments Practice Location: 349 Franklin Ave, 208, Nutley, NJ 07110 Phone: 888-299-9432 Fax: 973-472-1305 |
News Archive
Combination treatment prevents disease progression in patients with advanced melanoma
New data announced today has demonstrated that combinational treatment of cobimetinib with Zelboraf (vemurafenib), the first personalised medicine to extend life in the first-line setting for over 30 years, in patients with advanced melanoma (BRAFV600 mutation-positive) can prevent disease progression (progression-free survival; PFS) by 9.9 months compared to 6.2 months following treatment of vemurafenib alone.
Researchers explore effects of attention bias modification in adolescents with MDD
A study to be published in the March 2016 issue of the Journal of the American Academy of Child and Adolescent Psychiatry reports that adolescents with major depression who performed a computer-based task designed to shift attention from sad to neutral to positive word associations showed reductions in negative attention biases and clinician-rated depressive symptoms.
Bayer announces data from riociguat Phase III pulmonary arterial hypertension trial
Bayer HealthCare today announced data from the Phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid.
New gene linked to Tau pathology
Investigators at Rush University Medical Center and the Brigham and Women's Hospital in Boston reported the discovery of a new gene that is associated with susceptibility to a common form of brain pathology called Tau that accumulates in several different conditions, including Alzheimer's disease, certain forms of dementia and Parkinsonian syndromes as well as chronic traumatic encephalopathy that occurs with repeated head injuries.
› Verified 4 days ago
Dentists
Clinical Social Workers
Counselors
Pharmacists
Occupational Therapists
Psychologists